Aliases & Classifications for Cerebellar Disease

MalaCards integrated aliases for Cerebellar Disease:

Name: Cerebellar Disease 12 14
Cerebellar Diseases 42 69
Cerebellar Dysfunction 52
Cerebellar Disorders 41

Classifications:



External Ids:

Disease Ontology 12 DOID:2786
MeSH 42 D002526
UMLS 69 C0007760

Summaries for Cerebellar Disease

MedlinePlus : 41 when you play the piano or hit a tennis ball you are activating the cerebellum. the cerebellum is the area of the brain that controls coordination and balance. problems with the cerebellum include cancer genetic disorders ataxias - failure of muscle control in the arms and legs that result in movement disorders degeneration - disorders caused by brain cells decreasing in size or wasting away treatment of cerebellar disorders depends on the cause. in some cases, there is no cure but treatment may help with symptoms. nih: national institute of neurological disorders and stroke

MalaCards based summary : Cerebellar Disease, also known as cerebellar diseases, is related to cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1 and leukodystrophy, adult-onset, autosomal dominant, and has symptoms including ataxia, back pain and cerebellar ataxia. An important gene associated with Cerebellar Disease is CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Clonidine and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include cerebellum, brain and eye, and related phenotypes are behavior/neurological and nervous system

Related Diseases for Cerebellar Disease

Diseases related to Cerebellar Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
id Related Disease Score Top Affiliating Genes
1 cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1 11.3
2 leukodystrophy, adult-onset, autosomal dominant 10.9
3 ataxia, cerebellar, cayman type 10.8
4 polyglucosan body disease, adult form 10.8
5 medulloblastoma 10.6
6 cowden syndrome 1 10.6
7 cone-rod dystrophy 5 10.5 ATM CACNA1A
8 rigidity and multifocal seizure syndrome, lethal neonatal 10.5 ATXN3 ATXN7 CACNA1A
9 dandy-walker syndrome 10.5
10 spinocerebellar ataxia, autosomal recessive 18 10.4
11 spinocerebellar ataxia, autosomal recessive 17 10.4
12 spinocerebellar ataxia 31 10.4
13 spinocerebellar ataxia 41 10.4
14 spinocerebellar ataxia, autosomal recessive 7 10.4
15 spinocerebellar ataxia, autosomal recessive 12 10.4
16 spinocerebellar ataxia 20 10.4
17 spinocerebellar ataxia 42 10.4
18 spinocerebellar ataxia 21 10.4
19 spinocerebellar ataxia 12 10.4
20 spinocerebellar ataxia, autosomal recessive 21 10.4
21 spinocerebellar ataxia 28 10.4
22 spinocerebellar ataxia 19 10.4
23 spinocerebellar ataxia 1 10.4
24 spinocerebellar ataxia 5 10.4
25 spinocerebellar ataxia 26 10.4
26 spinocerebellar ataxia, autosomal recessive 11 10.4
27 spinocerebellar ataxia, autosomal recessive 23 10.4
28 spinocerebellar ataxia, autosomal recessive 14 10.4
29 spinocerebellar ataxia, autosomal recessive 22 10.4
30 spinocerebellar ataxia 38 10.4
31 spinocerebellar ataxia 6 10.4
32 spinocerebellar ataxia 34 10.4
33 spinocerebellar ataxia 2 10.4
34 mannosidosis, alpha-, types i and ii 10.4
35 spinocerebellar ataxia 15 10.4
36 spinocerebellar ataxia, autosomal recessive 20 10.4
37 spinocerebellar ataxia 13 10.4
38 spinocerebellar ataxia, autosomal recessive 10 10.4
39 spinocerebellar ataxia, autosomal recessive 13 10.4
40 spinocerebellar ataxia 8 10.4
41 spinocerebellar ataxia 14 10.4
42 spinocerebellar ataxia 7 10.4
43 spinocerebellar ataxia, autosomal recessive 8 10.4
44 spinocerebellar ataxia 27 10.4
45 spinocerebellar ataxia 36 10.4
46 spinocerebellar ataxia 43 10.4
47 spinocerebellar ataxia 17 10.4
48 spinocerebellar ataxia, autosomal recessive with axonal neuropathy 10.4
49 spinocerebellar ataxia 23 10.4
50 spinocerebellar ataxia, autosomal recessive 24 10.4

Graphical network of the top 20 diseases related to Cerebellar Disease:



Diseases related to Cerebellar Disease

Symptoms & Phenotypes for Cerebellar Disease

UMLS symptoms related to Cerebellar Disease:


ataxia, back pain, cerebellar ataxia, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, adiadochokinesis, dysdiadochokinesis, vertigo/dizziness, sleeplessness, cerebellar ataxia/dyskinesia

MGI Mouse Phenotypes related to Cerebellar Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 ZIC1 ATM ATXN2 ATXN3 ATXN7 CACNA1A
2 nervous system MP:0003631 9.36 ATM ATXN2 ATXN3 ATXN7 CACNA1A CALB1

Drugs & Therapeutics for Cerebellar Disease

Drugs for Cerebellar Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 213)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
3
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
4
Amantadine Approved Phase 4 768-94-5 2130
5
Dopamine Approved Phase 4,Phase 1,Phase 2,Early Phase 1 51-61-6, 62-31-7 681
6
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
7
Citalopram Approved Phase 4 59729-33-8 2771
8
Sertraline Approved Phase 4 79617-96-2 68617
9
Methylphenidate Approved, Investigational Phase 4,Phase 2 113-45-1 4158
10
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
11
Metformin Approved Phase 4 657-24-9 14219 4091
12 Adrenergic Agents Phase 4
13 Adrenergic Agonists Phase 4
14 Adrenergic alpha-2 Receptor Agonists Phase 4
15 Adrenergic alpha-Agonists Phase 4
16 Analgesics Phase 4,Phase 1,Phase 2
17 Antihypertensive Agents Phase 4,Phase 2
18 Autonomic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
19 Contraceptive Agents Phase 4
20 Estradiol 17 beta-cypionate Phase 4
21 Estradiol 3-benzoate Phase 4
22 Estradiol valerate Phase 4 979-32-8
23 Estrogens Phase 4
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
25 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
27 insulin Phase 4
28 Insulin, Globin Zinc Phase 4
29 Mitogens Phase 4
30 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Early Phase 1
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
32 Polyestradiol phosphate Phase 4
33 Sympatholytics Phase 4
34 Adjuvants, Immunologic Phase 4
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Antiviral Agents Phase 4,Phase 3,Phase 2
37 Interferon-beta Phase 4
38 interferons Phase 4,Phase 3,Phase 2
39 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
40 Antiparkinson Agents Phase 4
41 Dopamine Agents Phase 4,Phase 1,Phase 2,Early Phase 1
42 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Antidepressive Agents, Second-Generation Phase 4
44 Cholinergic Agents Phase 4,Phase 2,Phase 3
45 Cholinergic Antagonists Phase 4
46 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
47 Cytochrome P-450 Enzyme Inhibitors Phase 4
48 Dopamine Uptake Inhibitors Phase 4,Phase 2
49 Muscarinic Antagonists Phase 4
50 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 209)

id Name Status NCT ID Phase Drugs
1 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
2 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
3 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
4 An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia Completed NCT01716221 Phase 4 bupropion & Citalopram;Bupropion & Placebo;Placebo & Citalopram;Placebo & Placebo
5 Evaluation of Stress Disorders Completed NCT00050804 Phase 4 sertraline
6 Neuroimaging of the Effects of Concerta in the Treatment of ADHD Completed NCT00778310 Phase 4 methylphenidate-OROS;Placebo
7 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Recruiting NCT02733679 Phase 4 Metformin;Pioglitazone
8 Efficacy of Riluzole in Hereditary Cerebellar Ataxia Completed NCT01104649 Phase 2, Phase 3 riluzole;Placebo comparator
9 Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 Completed NCT01096082 Phase 2, Phase 3 Lithium Carbonate;Placebo
10 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3 Conjugated pneumococcal vaccine (Prevenar)
11 Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension) Completed NCT00993967 Phase 3 idebenone
12 A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients Completed NCT00905268 Phase 3 idebenone;Placebo
13 An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970111 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
14 A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970098 Phase 3 KPS-0373, High dose;KPS-0373, Low dose;Placebo
15 Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept Completed NCT00811681 Phase 3 pioglitazone;Placebo
16 A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970137 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
17 A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970124 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
18 Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich's Ataxia Study Completed NCT02593773 Phase 3 Interferon γ-1b
19 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Completed NCT02415127 Phase 3 Interferon γ-1b;Placebo
20 Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) Completed NCT01303406 Phase 3 Idebenone;Placebo
21 Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Completed NCT00697073 Phase 3 Idebenone
22 Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Completed NCT00537680 Phase 3 Idebenone;Idebenone;Placebo
23 STEADFAST Long-Term Safety Extension Completed NCT02797080 Phase 3 interferon γ-1b
24 A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) Completed NCT01662882 Phase 2, Phase 3 florbetapir (18F)
25 An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Recruiting NCT02889302 Phase 3 KPS-0373;Placebo
26 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Recruiting NCT02333305 Phase 3
27 EDS in Ataxia Telangiectasia Patients Recruiting NCT02770807 Phase 3 EDS-EP dose range of ~5-10 mg DSP/infusion;EDS-EP dose range of ~14-22 mg DSP/infusion;Placebo
28 Trial in Adult Subjects With Spinocerebellar Ataxia Active, not recruiting NCT02960893 Phase 2, Phase 3 BHV-4157;Placebo Comparator
29 Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia Terminated NCT00803868 Phase 2, Phase 3 varenicline;placebo
30 The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease Unknown status NCT02039206 Phase 2
31 A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation Unknown status NCT01489267 Phase 2
32 Clinical Study to Evaluate the Safety and Efficacy BMMNC in Cerebellar Ataxia Unknown status NCT01958177 Phase 1, Phase 2
33 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia Unknown status NCT01360164 Phase 1, Phase 2
34 4-Aminopyridine in Episodic Ataxia Type 2 Unknown status NCT01543750 Phase 2 4-Aminopyridine;Placebo
35 Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia Completed NCT00202397 Phase 2 Riluzole
36 High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration Completed NCT00034242 Phase 2 high-dose intravenous immunoglobulin (IVIG)
37 Idebenone to Treat Friedreich's Ataxia Completed NCT00229632 Phase 2 Idebenone
38 Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease Completed NCT02147886 Phase 2 Cabaletta for IV infusion once weekly during 24 weeks;Cabaletta for IV infusion once weekly during 24 weeks
39 Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 Completed NCT00992771 Phase 2 varenicline;placebo
40 Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia Completed NCT01016366 Phase 2 Lu AA24493;Placebo
41 A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01384435 Phase 2 KPS-0373;KPS-0373;KPS-0373;KPS-0373;Placebo
42 A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01004016 Phase 2 KPS-0373;Placebo
43 Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT00863538 Phase 2 KPS-0373
44 Iron-Chelating Therapy and Friedreich Ataxia Completed NCT00224640 Phase 1, Phase 2 Iron chelating intervention
45 A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients Completed NCT02035020 Phase 2 gamma interferon
46 Efficacy Study of Epoetin Alfa in Friedreich Ataxia Completed NCT01493973 Phase 2 Epoetin alfa;Placebo
47 Interferon Gamma-1b in Friedreich Ataxia (FRDA) Completed NCT01965327 Phase 2 Interferon Gamma-1b
48 Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia Completed NCT01350440 Phase 2
49 Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia Completed NCT00631202 Phase 2 Epoetin alfa
50 Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells Completed NCT01649687 Phase 1, Phase 2

Search NIH Clinical Center for Cerebellar Disease

Cochrane evidence based reviews: cerebellar diseases

Genetic Tests for Cerebellar Disease

Anatomical Context for Cerebellar Disease

MalaCards organs/tissues related to Cerebellar Disease:

39
Cerebellum, Brain, Eye, Testes, Heart, Spinal Cord, Cortex

Publications for Cerebellar Disease

Articles related to Cerebellar Disease:

(show top 50) (show all 93)
id Title Authors Year
1
Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease. ( 27957507 )
2017
2
Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review. ( 28689294 )
2017
3
Cerebellar Disease of Ruminants. ( 28166936 )
2017
4
Internally Versus Externally Cued Speech in Parkinson's Disease and Cerebellar Disease. ( 28654941 )
2017
5
Cerebellar Disease Mimicking Cerebrotendinous Xanthomatosis: Langerhans Cell Histiocytosis. ( 28554492 )
2017
6
A toolbox to visually explore cerebellar shape changes in cerebellar disease and dysfunction. ( 28479655 )
2016
7
The effect of a task-specific locomotor training strategy on gait stability in patients with cerebellar disease: a feasibility study. ( 27216372 )
2016
8
Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease. ( 27307499 )
2016
9
Using human induced pluripotent stem cells to model cerebellar disease: Hope and hype. ( 25985846 )
2015
10
Automated cerebellar lobule segmentation with application to cerebellar structural analysis in cerebellar disease. ( 26408861 )
2015
11
Acquired Esotropia in Cerebellar Disease: A Case Series Illustrating Misdiagnosis as Isolated Lateral Rectus Paresis and Progression Over Time. ( 27928333 )
2015
12
Assessment of postural stability in patients with cerebellar disease using gyroscope data. ( 26118512 )
2015
13
Effects of balance and gait rehabilitation in cerebellar disease of vascular or degenerative origin. ( 24398721 )
2014
14
Torpedo formation and Purkinje cell loss: modeling their relationship in cerebellar disease. ( 24590661 )
2014
15
Clinical manifestations of cerebellar disease. ( 25439285 )
2014
16
Training balance with opto-kinetic stimuli in the home: a randomized controlled feasibility study in people with pure cerebellar disease. ( 25082955 )
2014
17
Neuro-ophthalmic manifestations of cerebellar disease. ( 25439294 )
2014
18
Effects of task constraints on obstacle avoidance strategies in patients with cerebellar disease. ( 23022155 )
2013
19
Disturbed vestibular-neck interaction in cerebellar disease. ( 23081756 )
2013
20
Balance rehabilitation therapy by tongue electrotactile biofeedback in patients with degenerative cerebellar disease. ( 23232167 )
2012
21
Dichotic listening test in patients with chronic cerebellar disease. ( 22133971 )
2012
22
Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. ( 22140200 )
2012
23
Spike removal through multiscale wavelet and entropy analysis of ocular motor noise: a case study in patients with cerebellar disease. ( 21262262 )
2011
24
Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration. ( 22072678 )
2011
25
Vestibulo-cerebellar disease impairs the central representation of self-orientation. ( 21431098 )
2011
26
68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. ( 21157217 )
2011
27
Effects of cerebellar disease on sequences of rapid eye movements. ( 21385592 )
2011
28
Long-term effects of coordinative training in degenerative cerebellar disease. ( 20737551 )
2010
29
Longitudinal tracking of gait and balance impairments in cerebellar disease. ( 20544808 )
2010
30
Aphasia and neglect are uncommon in cerebellar disease: negative findings in a prospective study in acute cerebellar stroke. ( 20680538 )
2010
31
Intensive coordinative training improves motor performance in degenerative cerebellar disease. ( 19864636 )
2009
32
Time estimation in Parkinson's disease and degenerative cerebellar disease. ( 18580578 )
2008
33
Clinical manifestation of focal cerebellar disease as related to the organization of neural pathways. ( 18439215 )
2008
34
Reduced saccadic resilience and impaired saccadic adaptation due to cerebellar disease. ( 18184318 )
2008
35
Pediatric periodic alternating gaze deviation with midline cerebellar disease. ( 17280848 )
2007
36
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. ( 17404205 )
2007
37
The Croonian Lectures on the clinical symptoms of cerebellar disease and their interpretation. Lecture II. 1922. ( 17566247 )
2007
38
The Croonian Lectures On The Clinical Symptoms Of Cerebellar Disease And Their Interpretation. Lecture I. 1922. ( 17510914 )
2007
39
Clinical symptoms of cerebellar disease and their interpretation. ( 18041661 )
2007
40
Commentary on 'Holmes G. Clinical symptoms of cerebellar disease and their interpretation. Lecture I. The Lancet 1922;202 (Vol. 1 for 1922):1178-1182, and Holmes G. Clinical symptoms of cerebellar disease and their interpretation. Lecture II. The Lancet 1922;202 (Vol. 1 for 1922):1232-1237'. ( 17566248 )
2007
41
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. ( 17000981 )
2006
42
Studies of eccentric gaze stability: effects of pitch head position on horizontal gaze-holding in patients with cerebellar disease. ( 15827030 )
2005
43
Asymmetry of the pitch vestibulo-ocular reflex in patients with cerebellar disease. ( 15826988 )
2005
44
Cerebellar disease alters the axis of the high-acceleration vestibuloocular reflex. ( 16033941 )
2005
45
Diagnostic approach to cerebellar disease in children. ( 16417854 )
2005
46
Cerebellar disease and disease characterized by dysmetria or tremors. ( 15203226 )
2004
47
Single-neuron analysis of human thalamus in patients with intention tremor and other clinical signs of cerebellar disease. ( 11929926 )
2002
48
Dissociation of habit-learning in Parkinson's and cerebellar disease. ( 11970808 )
2002
49
Cerebellar-subcortical circuits and mania in cerebellar disease. ( 11207338 )
2001
50
Directional abnormalities of vestibular and optokinetic responses in cerebellar disease. ( 10372073 )
1999

Variations for Cerebellar Disease

Expression for Cerebellar Disease

Search GEO for disease gene expression data for Cerebellar Disease.

Pathways for Cerebellar Disease

GO Terms for Cerebellar Disease

Cellular components related to Cerebellar Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 APTX ATM ATXN10 ATXN2 ATXN3 ATXN7
2 nucleolus GO:0005730 9.65 APTX ATXN3 ATXN7 ITPR1 SETX
3 neuronal cell body GO:0043025 9.55 ATXN10 CACNA1A CALB1 PDYN SPTBN2
4 dendrite GO:0030425 9.1 ATXN10 CACNA1A CALB1 PDYN PRKCG SACS

Biological processes related to Cerebellar Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to pain GO:0048265 8.96 CACNA1A PRKCG
2 chemical synaptic transmission GO:0007268 8.92 ATXN3 CACNA1A PDYN PRKCG

Molecular functions related to Cerebellar Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 calcium ion transmembrane transporter activity GO:0015085 8.62 ATP2B3 ITPR1

Sources for Cerebellar Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....